Anti-Human CD40/TNFRSF5 Reference Antibody (Sotigalimab, RUO)

SKU: HB782116

Size:100ug

Description:The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to an announcement from Apexigen Inc., the drug developer.A novel, humanized monoclonal antibody, sotigalimab was designed to stimulate an antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.

Host species:Humanized

Tested applications:

Species reactivity:Human

Form:Liquid

Storage buffer:0.01M PBS, pH 7.4.

Purity:>95% purity as determined by SDS-PAGE.

Clonality:Monoclonal

Isotype:IgG1-Kappa

Applications:ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Target:Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40

Purification:Protein A/G purified from cell culture supernatant.

Endotoxin level:Please contact us for this information.

Expression system:Mammalian Cells

Accession:P25942

Stability and Storage:Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

Reconstitution:

Background:

Alternative Names:APX005M, APX-005, APX-005-M, APX-005M, 2305607-45-6

Clone ID:

Species:

Note:For research use only. Not suitable for clinical or therapeutic use.